NextCell Pharma Current Ratio vs. Shares Owned By Institutions
| NXTCL Stock | SEK 1.78 0.03 1.71% |
For NextCell Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NextCell Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NextCell Pharma AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NextCell Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NextCell Pharma AB over time as well as its relative position and ranking within its peers.
NextCell |
NextCell Pharma AB Shares Owned By Institutions vs. Current Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NextCell Pharma's current stock value. Our valuation model uses many indicators to compare NextCell Pharma value to that of its competitors to determine the firm's financial worth. NextCell Pharma AB is considered to be number one stock in current ratio category among its peers. It also is considered to be number one stock in shares owned by institutions category among its peers producing about 0.12 of Shares Owned By Institutions per Current Ratio. The ratio of Current Ratio to Shares Owned By Institutions for NextCell Pharma AB is roughly 8.02 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the NextCell Pharma's earnings, one of the primary drivers of an investment's value.NextCell Shares Owned By Institutions vs. Current Ratio
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
NextCell Pharma |
| = | 42.29 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
NextCell Pharma |
| = | 5.27 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
NextCell Shares Owned By Institutions Comparison
NextCell Pharma is currently under evaluation in shares owned by institutions category among its peers.
NextCell Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NextCell Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NextCell Pharma will eventually generate negative long term returns. The profitability progress is the general direction of NextCell Pharma's change in net profit over the period of time. It can combine multiple indicators of NextCell Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden. NextCell Pharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 10 people.
NextCell Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NextCell Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NextCell Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NextCell Pharma's important profitability drivers and their relationship over time.
Use NextCell Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NextCell Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NextCell Pharma will appreciate offsetting losses from the drop in the long position's value.NextCell Pharma Pair Trading
NextCell Pharma AB Pair Trading Analysis
The ability to find closely correlated positions to NextCell Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NextCell Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NextCell Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NextCell Pharma AB to buy it.
The correlation of NextCell Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NextCell Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NextCell Pharma AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NextCell Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your NextCell Pharma position
In addition to having NextCell Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Losers Thematic Idea Now
Latest Losers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Losers theme has 259 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Losers Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NextCell Stock Analysis
When running NextCell Pharma's price analysis, check to measure NextCell Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCell Pharma is operating at the current time. Most of NextCell Pharma's value examination focuses on studying past and present price action to predict the probability of NextCell Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCell Pharma's price. Additionally, you may evaluate how the addition of NextCell Pharma to your portfolios can decrease your overall portfolio volatility.